|
Online Database of Chemicals from Around the World | Search | Submit | Advertise |
Home >> Chemical Listing >> Apilimod>> Market Analysis Reports |
Market Analysis Reports of Apilimod |
|
4-{6-{2-[(3-Methylphenyl)-methylidene]-hydrazin-1-yl}-2-[2-(pyridin-2-yl)-ethoxy]-pyrimidin-4-yl}-morpholine (CAS 541550-19-0) Market Research Report 2025 BAC Reports offers its clients in-depth market research of chemical industry products on the global and regional markets (North & Latin America, Asia Pacific, European Union, Russia and CIS). Global Market Report of APILIMOD (CAS 541550-19-0) December 2024 Synta Pharmaceuticals Corp. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis ... for inflammatory diseases. Apilimod (IL-12 and IL-23 inhibitor): Apilimod (STA-5326) is an ... a Phase 2a clinical trial of Apilimod in patients with rheumatoid arthritis ... Additional IL-12/23 Inhibitors: In addition to Apilimod, the company has also identified ... 2020 COVID-19 Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 ... 1-7, Angiotensin receptor blocker, Anluohuaxian, AOIM - Z , Apilimod Dimesylate , Apixaban, APL-9, apocynin, Apremilast ... COVID-19 Therapy and Vaccine Drug Pipeline and Clinical Trials Report- September 2020 Update ... 1-7, Angiotensin receptor blocker, Anluohuaxian, AOIM - Z , Apilimod Dimesylate , Apixaban, APL-9, apocynin, Apremilast ... |